12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TD-9855: Development discontinued

Theravance disclosed in a November SEC filing that the company will discontinue development of TD-9855 to treat ADHD after data from a double-blind, U.S. Phase II trial showed the compound missed the primary endpoint of symptom reduction as measured by AISRS total score vs. placebo. TD-9855...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >